Refined atrial fibrillation screening and cost-effectiveness in the German population.
Renate B SchnabelChristopher WallenhorstDaniel EnglerStefan BlankenbergNorbert PfeifferNgoc Anh SpruenkerMatthias BuettnerMatthias MichalKarl J LacknerThomas MünzelPhilipp S WildCarlos MartinezBen Freedmannull nullPublished in: Heart (British Cardiac Society) (2021)
In our middle-aged population cohort, we identified 0.2% new AF by single timepoint screening. There was a significant estimated risk of stroke and heart failure in these individuals. Cost-effectiveness for screening may be reached in individuals aged 65 years and older. The simple age cut-off is not improved by using Nt-proBNP as a biomarker to guide a screening programme.